Check our latest Technology
NangioTx V-10
There are 8 million Americans living with PAD
Check our latest Technology
NangioTx V-10
There are 8 million Americans living with PAD

Who We Are

NangioTx’ team is made up of qualified experts in with extensive experience. Founders Dr. Kumar (CEO) a Bioengineer & Dr. Hartgerink (CTO) a Chemist have over 35 years of biomedical-research experience and produced over 100 publications in the areas of biomaterials and tissue engineering.

NangioTx is now building its team to translate V-10 into a therapeutic product. Leading the initiative for Investigational New Drug (IND) studies is Chief Scientific Officer (Dr. Karel Petrak).

Product Development

Technology

There are 8 million Americans living with PAD. In these patients, obstructed arteries result in poor blood flow (ischemia) to cardiac and peripheral tissues, and manifests in pain with walking (intermittent claudication).

Preclinical

Ischemic tissue repair represents a significant portion of the therapeutic market. The first indication we are targeting is peripheral artery disease, which is currently affecting 8 million Americans, and is slated to double by 2050.

Clinical

V-10 is a product of research that was performed at Rice University. NangioTx co-founders Vivek Kumar and Jeffrey Hartgerink are the inventors of V-10, for which a non-provisional patent was filed in August of 2014, and a patent was granted in September 2016.

Powered by keepvid themefull earn money